

ID NO:1 in said biological sample.

---

**18. (Reiterated.)** The method of claim 17, wherein before hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.

---

**19. (New.)** A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions; and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds the polypeptide of claim 1.

**20. (New.)** A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1; and
  - b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound; and
  - c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a deviation between the activities is indicative of a compound that modulates the activity of the polypeptide of claim 1.
- 

### REMARKS

Justification for the amendments is as follows. The amendments to claims 1 and 11-17 and new claims 19 and 20 were added to further clarify the invention. Support for the amendments to claim 1 are found, for example, in the specification on page 15, lines 24-27; page 50, line 4, to page 51, line 8; and page 51, lines 10-25. Support for new claim 19 is found, for example, in the specification on page 41, lines 11-29, and page 52, lines 10-15. Support for new

claim 20 is found, for example, in the specification on page 4, lines 18-28, and page 41, lines 11-16.

No new matter has been added by these amendments. Applicants respectfully request entry of the present amendments.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**.

**This form is enclosed in duplicate.**

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 2/22/00



Amir A. Naini, Reg. No. P-45,770

FOR: Danielle M. Pasqualone, Ph. D.

Reg. No. 43,847

Direct Dial Telephone: (650) 845-4892

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166